WallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for VRTX

Based on 16 analysts offering 12 month price targets for Vertex Pharmaceuticals Inc.
Min Forecast
$200.00+6.18%
Avg Forecast
$266.06+41.25%
Max Forecast
$331.00+75.73%

Should I buy or sell VRTX stock?

Strong Buy
Strong Buy
8 analysts 50%
Buy
5 analysts 31.25%
Hold
3 analysts 18.75%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

VRTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDate
Edward Tenthoff
Piper Sandler
Strong BuyMaintains$261.00+38.56%2021-06-14
Robyn Karnauskas
Truist Securities
Strong BuyMaintains$331.00+75.73%2021-06-14
Mohit Bansal
Citigroup
Strong BuyMaintains$285.00+51.31%2021-06-11
Anonymous
Goldman Sachs
Strong BuyMaintains$307.00+62.99%2021-06-11
Alethia Young
Cantor Fitzgerald
Strong BuyMaintains$281.00+49.18%2021-06-11
Paul Matteis
Stifel Nicolaus
Strong BuyMaintains$244.00+29.54%2021-06-11
Gena Wang
Barclays
Strong BuyMaintains$285.00+51.31%2021-06-11
Colin Bristow
UBS
Strong BuyInitiates Coverage On$287.00+52.37%2020-10-28
Brian Skorney
Baird
BuyMaintains$240.00+27.42%2021-06-11
Brian Abrahams
RBC Capital
BuyMaintains$242.00+28.48%2021-06-11

1 of 2

Forecast return on equity

Is VRTX forecast to generate an efficient return?
Company
37.99%
Industry
4.87%
Market
61.45%
VRTX's Return on Equity is forecast to be high in 3 years (37.99%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is VRTX forecast to generate an efficient return on assets?
Company
28.16%
Industry
7.64%
Market
19.05%
VRTX is forecast to generate higher Return on Assets (28.16%) than the US Biotechnology industry average (7.64%)
Forecast

VRTX earnings per share forecast

What is VRTX's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$9.42-11.51%
Avg 2 year Forecast
$10.33-2.9%
Avg 3 year Forecast
$12.29+15.51%
VRTX's earnings are forecast to grow at a rate of 3.06% per year, which is not exceptional
Forecast

VRTX revenue forecast

What is VRTX's revenue in the next 3 years based on estimates from 9 analysts?
Avg 1 year Forecast
$6.9B+7.8%
Avg 2 year Forecast
$7.6B+18.17%
Avg 3 year Forecast
$8.3B+28.63%
VRTX's revenue is forecast to grow at a rate of 8.75% per year, which is not exceptional
Forecast

VRTX earnings growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
3.06%
Industry
28.73%
Market
19.61%
VRTX's earnings are forecast to grow slower (3.06% per year) than the US Biotechnology industry average (28.73%)
Forecast
VRTX's earnings are forecast to grow slower (3.06% per year) than the US market average (19.61%)
Forecast
VRTX's earnings are forecast to grow faster (3.06% per year) than the risk-free savings rate (1.5%)
Forecast

VRTX revenue growth forecast

How is VRTX forecast to perform vs Biotechnology companies and vs the US market?
Company
8.75%
Industry
54.18%
Market
14.6%
VRTX's revenues are forecast to grow slower (8.75% per year) than the US Biotechnology industry average (54.18%)
Forecast
VRTX's revenues are forecast to grow slower (8.75% per year) than the US market average (14.6%)
Forecast

Vertex Pharmaceuticals Stock Forecast FAQ

Is Vertex Pharmaceuticals Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: VRTX) stock is to Strong Buy VRTX stock.

Out of 16 analysts, 8 (50%) are recommending VRTX as a Strong Buy, 5 (31.25%) are recommending VRTX as a Buy, 3 (18.75%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

What is VRTX's earnings growth forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual earnings growth rate of 3.06% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 28.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.61%.

Vertex Pharmaceuticals's earnings in 2021 is $2,762,032,000.On average, 8 Wall Street analysts forecast VRTX's earnings for 2021 to be $2,437,220,292, with the lowest VRTX earnings forecast at $1,726,634,026, and the highest VRTX earnings forecast at $2,588,656,710. On average, 8 Wall Street analysts forecast VRTX's earnings for 2022 to be $2,674,418,907, with the lowest VRTX earnings forecast at $2,197,769,547, and the highest VRTX earnings forecast at $2,935,536,709.

In 2023, VRTX is forecast to generate $3,181,459,097 in earnings, with the lowest earnings forecast at $3,181,459,097 and the highest earnings forecast at $3,181,459,097.

What is VRTX's revenue growth forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 8.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.6%.

Vertex Pharmaceuticals's revenue in 2021 is $6,414,881,000.On average, 9 Wall Street analysts forecast VRTX's revenue for 2021 to be $1,790,197,714,487, with the lowest VRTX revenue forecast at $1,767,389,319,081, and the highest VRTX revenue forecast at $1,824,254,858,761. On average, 10 Wall Street analysts forecast VRTX's revenue for 2022 to be $1,962,260,030,956, with the lowest VRTX revenue forecast at $1,889,530,426,360, and the highest VRTX revenue forecast at $2,048,921,785,965.

In 2023, VRTX is forecast to generate $2,135,961,484,854 in revenue, with the lowest revenue forecast at $1,967,896,830,942 and the highest revenue forecast at $2,368,646,776,217.

What is VRTX's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: VRTX) forecast ROA is 28.16%, which is higher than the forecast US Biotechnology industry average of 7.64%.

What is VRTX's Price Target?

According to 16 Wall Street analysts that have issued a 1 year VRTX price target, the average VRTX price target is $266.06, with the highest VRTX stock price forecast at $331.00 and the lowest VRTX stock price forecast at $200.00.

On average, Wall Street analysts predict that Vertex Pharmaceuticals's share price could stay at $266.06 by Jun 14, 2022. The average Vertex Pharmaceuticals stock price prediction forecasts a potential downside of N/A from the current VRTX share price of $188.36.

What is VRTX's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: VRTX) Vertex Pharmaceuticals's current Earnings Per Share (EPS) is $10.64. On average, analysts forecast that VRTX's EPS will be $9.42 for 2021, with the lowest EPS forecast at $6.67, and the highest EPS forecast at $10.00. On average, analysts forecast that VRTX's EPS will be $10.33 for 2022, with the lowest EPS forecast at $8.49, and the highest EPS forecast at $11.34. In 2023, VRTX's EPS is forecast to hit $12.29 (min: $12.29, max: $12.29).

What is VRTX's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: VRTX) forecast ROE is 37.99%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.